Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Syncor Xigris Delivery For Lilly Is First Non-Radiopharmacy Agreement

Executive Summary

Syncor's agreement to provide emergency delivery of Lilly's pending sepsis agent Xigris (drotrecogin alfa) is the company's first distribution deal outside of radiopharmacy.

You may also be interested in...



Cardinal To Run Xigris Emergency Distribution Via Acquisition Of Syncor

Cardinal will be the emergency supplier of Lilly's sepsis agent Xigris following the wholesaler's acquisition of the nuclear pharmacy company Syncor

Cardinal To Run Xigris Emergency Distribution Via Acquisition Of Syncor

Cardinal will be the emergency supplier of Lilly's sepsis agent Xigris following the wholesaler's acquisition of the nuclear pharmacy company Syncor

Idec Zevalin NHL Indication Split By Accelerated/Standard Approval

Idec/Genentech will conduct a postmarketing study of Zevalin in non-Hodgkin's lymphoma patients who have not failed Rituxan therapy to fulfill accelerated approval requirements

Related Content

UsernamePublicRestriction

Register

PS038422

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel